Efficacy and safety of autologous stem cell transplantation after induction therapy with lenalidomide, bortezomib, and dexamethasone - Aix-Marseille Université Access content directly
Journal Articles European Journal of Haematology Year : 2019

Efficacy and safety of autologous stem cell transplantation after induction therapy with lenalidomide, bortezomib, and dexamethasone

Abstract

Recently, phase III trials assessed a new combination of lenalidomide, bortezomib, and dexamethasone (RVD) in induction therapy in transplantation‐eligible multiple myeloma (MM) patients, before consolidation with RVD and lenalidomide maintenance. We present a retrospective study evaluating this approach with patients from the real life.
Fichier principal
Vignette du fichier
Revised Manuscript VRD EJH Final version.pdf (197.23 Ko) Télécharger le fichier
Origin : Files produced by the author(s)
Loading...

Dates and versions

hal-02267221 , version 1 (18-10-2019)

Identifiers

Cite

Robin Arcani, Geoffroy Venton, Julien Colle, Pierre Suchon, Vadim Ivanov, et al.. Efficacy and safety of autologous stem cell transplantation after induction therapy with lenalidomide, bortezomib, and dexamethasone. European Journal of Haematology, 2019, ⟨10.1111/ejh.13297⟩. ⟨hal-02267221⟩

Collections

INSERM UNIV-AMU
94 View
365 Download

Altmetric

Share

Gmail Facebook X LinkedIn More